Roche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012

Size: px
Start display at page:

Download "Roche Diagnostics. Daniel O Day COO Roche Diagnostics. Vontobel Summer Conference June 22, 2012"

Transcription

1

2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 0 loss of key executives or other employees; and adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected

3 Roche Diagnostics Daniel O Day COO Roche Diagnostics Vontobel Summer Conference June 22, 202

4 Roche Group performance update Roche Diagnostics

5 Q 202: Highlights Sales Group and Pharma: +2% (+3% excluding Tamiflu) Diagnostics: +4% Negative currency impact (-3%p) 2 Approvals of New Molecular Entities Erivedge in advanced basal cell carcinoma approved in US Zelboraf in metastatic melanoma approved in EU 5 positive late-stage trials and regulatory filings Avastin in metastatic colorectal cancer: treatment through multiple lines (TML) T-DM in HER2+ metastatic breast cancer (EMILIA) Herceptin subcutaneous in HER2+ breast cancer (HANNAH)-filed in EU Actemra in polyarticular-course juvenile idiopathic arthritis (CHERISH) Actemra in rheumatoid arthritis (ADACTA) at Constant Exchange Rates 5

6 Q 202: Group sales On track to meet full-year guidance change in % CHF m CHF m CHF CER Pharmaceuticals Division 8,624 8,72-2 Diagnostics Division 2,403 2, Roche Group,027,20-2 CER=Constant Exchange Rates 6

7 Outlook for 202 confirmed Sales growth (CER) Operational Excellence savings Core EPS growth target (CER) Dividend outlook Group & Pharma: low to mid-single digit Diagnostics: above market 202+ : CHF 2.4 bn* High single-digit Continue attractive dividend policy Barring unforeseen events; CER=Constant Exchange Rates; * vs. 20: CHF.8 bn 7

8 Roche Group performance update Roche Diagnostics

9 Q 202: Diagnostics Division sales Strong growth in Professional, Molecular and Tissue Diagnostics change in % CHF m CHF m CHF CER Diagnostics Division 2,403 2, Professional Diagnostics,224,7 5 9 Diabetes Care Molecular Diagnostics Applied Science Tissue Diagnostics CER = Constant Exchange Rates 20 sales restated from Diabetes Care (full year impact CHF 23 m) to Professional Diagnostics (CHF +23 m full year impact) 9

10 Q 202: Diagnostics Division sales Strong growth in all regions except for EMEA North America +7% 25% of divisional sales EMEA -% 48% of divisional sales Japan +0% 6% of divisional sales Latin America +9% 7% of divisional sales Asia Pacific +3% 4% of divisional sales Europe, Middle East and Africa; All growth at CER (Constant Exchange Rates) 0

11 Q 202: Diagnostics Division highlights CHF bn Q 202 vs. Q 20 CER growth Professional Dia +9% Strong market uptake of Vitamin D total; expansion of Hepatitis menu; launch of new automation and IT systems Diabetes Care -7% Reimbursement changes in some EMEA countries; expected launch of Accu-Chek Nano SmartView in US and Accu-Chek Mobile in Europe in 2Q 202 Molecular Dia +8% Strong sales in blood screening and HCV monitoring; FDA approval of cobas CT/NG test; new cervical cancer screening guidelines in US Applied Science -4% Continued global slowdown in research funding; strong sales to industrial manufacturing customers Tissue Dia +8% EMEA North America RoW Strong growth ahead of market; expansion of breast cancer diagnostics offering; new companion diagnostics partnerships EMEA = Europe, Middle East and Africa, APAC = Asia Pacific CER = Constant Exchange Rates

12 Launch of next-generation Accu-Chek product portfolio to strengthen market position Accu-Chek Mobile Accu-Chek Nano SmartView Accu-Chek Nano SmartView - Small, no-code blood glucose monitoring (bgm) system with sleek design and improved functions - U.S. launch expected in mid-april Accu-Chek Mobile - Next-generation strip-free system that simplifies SMBG*, is preferred by high frequency testers - Launch in EMEA to revive sales growth * Self-monitoring of blood glucose 2

13 New cervical cancer screening guidelines in US HPV co-testing and genotyping strongly recommended cobas HPV Test Three results in one test 2 HR HPV pool HPV Genotype 6 HPV Genotype 8 New cervical cancer guidelines by leading US organizations HPV and cytology co-testing in women >30yrs HPV 6 & 8 genotyping in women pap(-) and HPV(+) recommended cobas HPV test numerous contract wins in US ATHENA data primary screening filing expected in 203 American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology 3

14 Strengthening our infectious diseases portfolio Launch of new HCV tests New oral therapies increase number of HCV patients treated Roche offers comprehensive menu of tests for: HCV detection genotyping viral load testing blood screening Screening and diagnosis Treatment Evaluate treatment duration Treatment follow-up Elecsys anti-hcv II New! COBAS HCV Qualit. v2.0 New! COBAS HCV Quantitative Test, v2.0 New! COBAS AmpliPrep/COBAS TaqMan HCV Quantitative & QualitativeTests, v2.0. Not available in the US 4

15 Premium for innovation Focus in Personalised Healthcare Exploiting advantages of Diagnostics and Pharma Focus Pharma Dia MedTech OTC Generics Differentiation 5

16 Roche Diagnostics commitment to PHC Preferred Partner for Companion Diagnostics (CDx) Internal collaborations > External collaborations Personalized Healthcare collaborations with more than 30 pharma and biotech companies Including R&D collaborations and CDx projects Tissue Diagnostics signs 5 new partnerships - Pfizer (Crizotinib ALK IHC) - Syndax (Entinostat- E-cadherin) - Aeterna Zentaris (AEZS 08 LHRH) - Bayer (antibody-drug conjugate) - Seattle Genetics & Millennium Pharma (ADCETRIS CD30) 6

17 Key launches 202 Area Product Market BA* Labs cobas t 6 - Coagulation analyzer BenchMark Special Stains - Tissue stainer VENTANA iscan HT - Digital tissue scanner EU WW EU, US RPD RTD RTD Instruments / Devices Point of Care Diabetes Care cobas b 0 - Multi lipid and glucose analyzer cobas b 23 - Blood gas analyzer Accu-Chek Nano SmartView -Small, no-code bgm system Accu-Chek Combo Insulin pump & bg meter combined Accu-Chek Mobile Next generation strip free bgm system SOLO Micropump Insulin pump and bg meter combined EU US US US EU EU RPD RPD RDC RDC RDC RDC Tests/ Assays Oncology Infectious Diseases HE4 - Ovarian cancer ER Breast cancer CINtec p6 Histology- Cervical cancer GS GType Sequencing Primer Sets- Leukemia CMV Cytomegalovirus infections CT/NG - Chlamydia and gonorrhoea infections US US EU, US WW US US RPD RTD RTD RAS RMD RMD Metabolism Vitamin D total - Vitamin D2 & D3 US RPD Achieve sales growth above the market * Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics ; RAS: Roche Applied Science; RTD: Roche Tissue Diagnostics; blood glucose monitoring 7

18 We Innovate Healthcare

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011

Roche Diagnostics Daniel O Day COO Roche Diagnostics. Société Générale - The Premium Review Conference, Paris December 2, 2011 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Diagnostics Division. Daniel O Day COO Roche Diagnostics

Diagnostics Division. Daniel O Day COO Roche Diagnostics 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Diagnostics Division. Daniel O Day COO Roche Diagnostics

Diagnostics Division. Daniel O Day COO Roche Diagnostics 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,

More information

Science, patient benefits and productivity

Science, patient benefits and productivity Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Innovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015

Innovation and value creation. Severin Schwan, CEO Roche Group. Zurich, January 2015 Innovation and value creation Severin Schwan, CEO Roche Group Zurich, January 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words

More information

Roche on track for full-year targets good sales growth in first quarter

Roche on track for full-year targets good sales growth in first quarter Investor Update Basel, 12 April 2012 Roche on track for full-year targets good sales growth in first quarter Group sales rise 2% at CER 1 (-1% in Swiss francs; +1% in US dollars) to 11.0 billion Swiss

More information

Roche Group posts strong sales growth in the third quarter. Cancer medicines and clinical lab business drive Group performance

Roche Group posts strong sales growth in the third quarter. Cancer medicines and clinical lab business drive Group performance Media Release Basel, 16 October 2012 Roche Group posts strong sales growth in the third quarter Group sales rise 4% at CER 1 to 33.7 billion Swiss francs (+7% in Swiss francs) in the first nine months

More information

Focus and value creation

Focus and value creation Focus and value creation Karl Mahler: Head IR Stefan Frings: Medical Affairs Director Germany London, November 2014 This presentation contains certain forward-looking statements. These forward-looking

More information

Roche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010

Roche Lazard Capital Markets 7 th Annual Healthcare Conference. Thomas Kudsk Larsen, 17 November 2010 Roche Lazard Capital Markets 7 th Annual Healthcare Conference Thomas Kudsk Larsen, 17 November 2010 This presentation contains certain forward-looking statements. These forward-looking statements may

More information

Roche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011

Roche Committed to innovation and profitable growth. Dr. Alan Hippe CFO Roche. Zurich, May 2011 Roche Committed to innovation and profitable growth Dr. Alan Hippe CFO Roche Zurich, May 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Operating free cash flow rises 10% to 15.4 billion Swiss francs. HER2-franchise strengthened by Perjeta launch, filing of T-DM1 in US and Europe

Operating free cash flow rises 10% to 15.4 billion Swiss francs. HER2-franchise strengthened by Perjeta launch, filing of T-DM1 in US and Europe Media Release Yes, let s see, may Basel, 30 January 2013 Roche delivers strong 2012 results Group sales rise 4% 1 to 45.5 billion Swiss francs due to oncology sales, clinical laboratory business Core EPS

More information

Roche delivers good sales growth in the first nine months of 2016

Roche delivers good sales growth in the first nine months of 2016 Investor Update Basel, 20 October 2016 Roche delivers good sales growth in the first nine months of 2016 Group sales increase 4% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division

More information

Sales CHF millions As % of sales % change. In CHF Group sales 12,942 12,

Sales CHF millions As % of sales % change. In CHF Group sales 12,942 12, Investor Update Basel, 27 April 2017 Roche reports a good start in 2017 Group sales increase 4% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq

More information

Diagnostics Division Daniel O Day COO Roche Diagnostics

Diagnostics Division Daniel O Day COO Roche Diagnostics Diagnostics Division Daniel O Day COO Roche Diagnostics 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects,

More information

Translating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals

Translating excellence in science into customer benefit. Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Translating excellence in science into customer benefit Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals Barclays Healthcare Conference, Miami March 16, 2011 This presentation contains certain

More information

Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs

Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs Media Release Basel, 24 July 2014 Roche with good half year performance Group sales up 5% at constant exchange rates 1, -1% in Swiss francs Core earnings per share up 7% at constant exchange rates, 0%

More information

Roche at a Glance An Introduction to our Company. February 2013

Roche at a Glance An Introduction to our Company. February 2013 Roche at a Glance An Introduction to our Company February 2013 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active

More information

Sales CHF millions As % of sales % change. January - March CER CHF Group sales 13,583 12,

Sales CHF millions As % of sales % change. January - March CER CHF Group sales 13,583 12, Investor Update Basel, 26 April 2018 Roche reports a strong start in 2018 Group sales increase 6% 1 at constant exchange rates and 5% in Swiss francs Pharmaceuticals Division sales up 7%, driven mainly

More information

Nine months ended 30 September At CER* In CHF In USD Pharmaceuticals Division Excluding Tamiflu 24,397 24,096 28,395 27,587

Nine months ended 30 September At CER* In CHF In USD Pharmaceuticals Division Excluding Tamiflu 24,397 24,096 28,395 27,587 Media Release Basel, 3 October 20 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-2% in Swiss

More information

Investor Update. Roche in 2011: Strong results and positive outlook. Basel, 1 February 2012

Investor Update. Roche in 2011: Strong results and positive outlook. Basel, 1 February 2012 Investor Update Basel, February 0 Roche in : Strong results and positive outlook Group sales rise % (-0% in Swiss francs; +6% in US dollars), excluding Tamiflu. Significant foreign exchange impact of percentage

More information

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011 Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee

More information

1 Pharmaceutical Division 42, Diagnostics Division 32,794 9,737

1 Pharmaceutical Division 42, Diagnostics Division 32,794 9,737 Investor Update Yes, let s see, may Basel, 30 January 2013 Roche delivers strong 2012 results Group sales rise 4% 1 to 45.5 billion Swiss francs due to oncology sales, clinical laboratories business Core

More information

Investor Update. Roche posts strong first-half results. Úten morgen her speck! Basel, 25 July 2013

Investor Update. Roche posts strong first-half results. Úten morgen her speck! Basel, 25 July 2013 Investor Update Úten morgen her speck! Basel, 25 July 2013 Roche posts strong first-half results Group sales 5% 1 higher at 23.3 billion Swiss francs Core EPS 12% higher at 7.58 Swiss francs; net income

More information

Taiwan s Premier Biopharma and the future leader in Immuno-Oncology

Taiwan s Premier Biopharma and the future leader in Immuno-Oncology 1 Taiwan s Premier Biopharma and the future leader in Immuno-Oncology Safe Harbor Statement This presentation contains certain forwardlooking statements. These forward-looking statements may be identified

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs

Core earnings per share up 7% at constant exchange rates, 0% in Swiss francs Investor Update Basel, 24 July 2014 Roche with good half year performance Group sales up 5% at constant exchange rates 1, -1% in Swiss francs Core earnings per share up 7% at constant exchange rates, 0%

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Roland Diggelmann, CEO Roche Diagnostics Paris, November 30, 2016 Q3 2016 Group results Diagnostics Business model & strategy Q3 2016 overview Investing in innovation

More information

Fitting the Treatment to the Patient Roche Personalized Healthcare. February 24, 2012

Fitting the Treatment to the Patient Roche Personalized Healthcare. February 24, 2012 Fitting the Treatment to the Patient Roche Personalized Healthcare February 24, 2012 Roche Group Pharmaceuticals Roche Pharma Genentech Chugai Applied Science Molecular Professional Tissue Diabetes Care

More information

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Developing & Commercializing Targeted Small Molecule Drugs in Cancer Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Roche reports strong sales growth in the first nine months of Sales CHF millions As % of sales % change

Roche reports strong sales growth in the first nine months of Sales CHF millions As % of sales % change Investor Update Basel, 19 October 2017 Roche reports strong sales growth in the first nine months of 2017 Group sales increase 5% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division

More information

Roche. Pascal Soriot COO Roche Pharmaceuticals

Roche. Pascal Soriot COO Roche Pharmaceuticals 1 Roche Pascal Soriot COO Roche Pharmaceuticals 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Cowen Investor Conference March confidently live life with ease

Cowen Investor Conference March confidently live life with ease Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

Roche delivers continued growth in the first half of 2016

Roche delivers continued growth in the first half of 2016 Investor Update Basel, 21 July 2016 Roche delivers continued growth in the first half of 2016 Group sales increased by 5% 1 at constant exchange rates, 6% in Swiss francs Pharmaceuticals Division sales

More information

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004

Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations

More information

Core EPS growth ahead of sales, up 10% to Swiss francs

Core EPS growth ahead of sales, up 10% to Swiss francs Investor Update Basel, 30 January 2014 Roche delivers strong 2013 results Group sales rise 6% 1 to 46.8 billion Swiss francs Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin,

More information

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1

International Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1 Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking

More information

Roche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials

Roche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials Media Release Basel, 14 April 2011 Roche Group s first-quarter 2011 sales on track for full-year targets positive results in seven key clinical trials Group Group sales stable in local currencies (-9%

More information

2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and

2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and Appendix: Tables 1. Sales January to March 2016 and 2015... 2 2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and 2015... 3 3. Pharmaceuticals Division... 4 4. Top 20 Pharmaceuticals

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical

More information

Photocure ASA Executing the Strategy

Photocure ASA Executing the Strategy Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Stefan Frings - Medical Director Germany London November 2016 2 This presentation contains certain forward-looking statements. These forward-looking statements may be

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Opportunities and Challenges in the Development of Companion Diagnostics

Opportunities and Challenges in the Development of Companion Diagnostics Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine

More information

Putting ALK on the right growth trajectory

Putting ALK on the right growth trajectory Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large

More information

Building a Premier Oncology Biotech

Building a Premier Oncology Biotech Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation

More information

JP Morgan Healthcare Conference

JP Morgan Healthcare Conference JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and

More information

Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference

Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's

More information

Roche results. January 30, 2013

Roche results. January 30, 2013 1 Roche 2012 results January 30, 2013 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology

More information

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( ) Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United

More information

Innovation and value creation

Innovation and value creation Innovation and value creation Severin Schwan, CEO Roche Bank am Bellevue Zuerich, January 2017 1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Positioned for Growth

Positioned for Growth Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation

More information

Another Record Year for Bayer HealthCare Pharmaceuticals in Asia Pacific

Another Record Year for Bayer HealthCare Pharmaceuticals in Asia Pacific News Release Bayer (South East Asia) Pte Ltd Communications 63 Chulia Street OCBC Centre East, 14 th Floor Singapore 049514 Tel. +65 6496 1888 Co. No.: 197901344Z Another Record Year for Bayer HealthCare

More information

Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage

Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies

More information

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions

More information

Treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO):

Treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO): Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Treatment of visual impairment due to macular edema secondary to branch retinal

More information

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 (Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation

More information

Enhancing Corporate Value

Enhancing Corporate Value Goldman Sachs Twenty Sixth Annual Healthcare Conference Enhancing Corporate Value Eisai Co., Ltd. June 15, 2005 Please refer to the US Roadshow, June 2005 material in our WEB site for further information

More information

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday

More information

Pascal Soriot, Head of Strategic Marketing

Pascal Soriot, Head of Strategic Marketing Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage

More information

Roche. Q sales. April 11, 2013

Roche. Q sales. April 11, 2013 1 Roche Q1 2013 sales April 11, 2013 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates,

More information

Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI (crizotinib)

Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI (crizotinib) Merck Media: Markus Talanow +49 6151 72 7144 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 News Release April 7, 2015 Not

More information

Roche reports strong performance in the first half of 2017

Roche reports strong performance in the first half of 2017 Investor Update Basel, 27 July 2017 Roche reports strong performance in the first half of 2017 Group sales increase 5% 1 at constant exchange rates and in Swiss francs Pharmaceuticals Division sales up

More information

Myriad Genetics Corporate Presentation 6/4/13

Myriad Genetics Corporate Presentation 6/4/13 Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events

More information

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016

Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other

More information

Global Prefilled Syringes Market: Trends, Opportunities and Forecasts ( )

Global Prefilled Syringes Market: Trends, Opportunities and Forecasts ( ) Global Prefilled Syringes Market: Trends, Opportunities and Forecasts (2016-2021) By Material - Glass and Plastic By Filling Capabilities Single Chamber and Dual/Multiple Chamber By Major Applications

More information

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

Photocure ASA Executing the Strategy

Photocure ASA Executing the Strategy Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events

More information

Roche delivers strong performance in the first half of 2015

Roche delivers strong performance in the first half of 2015 Investor Update Basel, 23 July Roche delivers strong performance in the first half of 2015 Group sales up 6% at constant exchange rates 1, 3% in Swiss francs Pharmaceuticals Division sales up 5%, driven

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%

More information

Food & Beverages Food for a growing world

Food & Beverages Food for a growing world Food & Beverages Food for a growing world Rasmus von Gottberg, Vice President F&B Marketing, Novozymes Christel Thea Jørgensen, Vice President R&D, Novozymes Jeremy Bentham, Go to Market Director, Cargill

More information

Roche: Committed to Innovation

Roche: Committed to Innovation Roche: Committed to Innovation William M. Burns CEO Roche Pharmaceuticals UBS Swiss Equity Conference, Zurich, 26. November 2009 This presentation contains certain forward-looking statements. These forward-looking

More information

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company

More information

Pharmaceutical market

Pharmaceutical market Pharmaceutical market I s P h a r m a a s i m p o r t a n t a s i t s e m p l o y e e s t h i n k? Our lives are getting longer In Europe, over the last 65 years, we have obeserved a significant increase

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

Leading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products

Leading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio

More information

Beyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective

Beyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective Beyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective IAIM Regional Meeting for the Americas and Europe 1 February 2017 Anupama Tantri

More information

Innovation and growth

Innovation and growth Innovation and growth Bill Anderson Head of Global Product Strategy and Chief Marketing Officer Jefferies Healthcare Conference London, November 2014 This presentation contains certain forward-looking

More information

GLOBAL REGISTRATION STRATEGIES:

GLOBAL REGISTRATION STRATEGIES: GLOBAL REGISTRATION STRATEGIES: Therapeutic Product (TP) and the Companion Diagnostic (CDx) Erin Pedalino Regulatory Affairs International MSD Unique Role as CDx Regulatory Liaison at a Therapeutic Product

More information

For personal use only

For personal use only Targeted DEP shows sustained superior performance in ovarian cancer model Melbourne, Australia; 2 February 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the final results of the preclinical

More information

Welcome to the Full -Year Results Press Conference

Welcome to the Full -Year Results Press Conference Welcome to the Full -Year Results Press Conference Disclamer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements

More information

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,

More information

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase

More information

Slide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes

Slide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the

More information

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018 Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic

More information

Merck Pipeline. November 1, 2017

Merck Pipeline. November 1, 2017 Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such

More information

Myriad Genetics Corporate Presentation 06/13/2018

Myriad Genetics Corporate Presentation 06/13/2018 Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today

More information

Consumer Care A Strong Foundation in Consumer Health

Consumer Care A Strong Foundation in Consumer Health Consumer Care A Strong Foundation in Consumer Health Spring Investors Conference 2004 Leverkusen, March 19, 2004 Gary S. Balkema President Consumer Care Division Safe Harbor This presentation contains

More information